Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Heptares Therapeutics Limited patents


Recent patent applications related to Heptares Therapeutics Limited. Heptares Therapeutics Limited is listed as an Agent/Assignee. Note: Heptares Therapeutics Limited may have other listings under different names/spellings. We're not affiliated with Heptares Therapeutics Limited, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "H" | Heptares Therapeutics Limited-related inventors


Muscarinic agonists

This invention relates to compounds that are agonists of the muscarinic m4 receptor and/or m4 receptor and which are useful in the treatment of muscarinic m1/m4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. ... Heptares Therapeutics Limited

Muscarinic agonists

This invention relates to compounds that are agonists of the muscarinic m1 receptor and/or m4 receptor and which are useful in the treatment of muscarinic m1/m4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. ... Heptares Therapeutics Limited

Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists

This invention relates to compounds that are agonists of the muscarinic m1 receptor and/or m4 receptor and which are useful in the treatment of muscarinic m1/m4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. ... Heptares Therapeutics Limited

Muscarinic m1 receptor agonists

. . . . This invention relates to compounds that are agonists of the muscarinic m1 receptor and which are useful in the treatment of muscarinic m1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. ... Heptares Therapeutics Limited

Mutant g-protein coupled receptors and methods for selecting them

. . The invention relates to mutant g-protein coupled receptors with increased conformational stability, and methods of use thereof. In some aspects, polynucleotides encoding the mutant g-protein coupled receptors are provided. ... Heptares Therapeutics Limited

Spirocyclic compounds as agonists of the muscarinic m1 receptor and/or m4 receptor

This invention relates to compounds that are agonists of the muscarinic m1 and/or m4 receptor and which are useful in the treatment of muscarinic m1/m4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. ... Heptares Therapeutics Limited

1,2,4-triazine-4-amine derivatives

. . . . . . According to the invention there is provided a compound of formula a1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the a1-a21, or, particularly, the a2, receptor wherein the compound of formula a1 has the structure, wherein, a represents cy1 or heta; cy1 represents a 5- to 14-membered aromatic, fully saturated or partially unsaturated carbocylic ring system comprising one, two or three rings, which cy1 group is optionally substituted by one or more r4a substituents; heta represents a 5- to 14-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from o, s and n, which heterocyclic group may comprise one, two or three rings and which heta group is optionally substituted by one or more r4b substituents; b represents a cy2 or hetb; cy2 represents a 3- to 10-membered aromatic, fully saturated or partially unsaturated carbocyclic ring system comprising one or two rings, which cy2 group is optionally substituted by one or more r4c substituents; hetb represents a 3- to 10-membered heterocyclic group that may be aromatic, fully saturated or partially unsaturated, and which contains one or more heteroatoms selected from o, s and n, which heterocyclic group may comprise one or two rings and which hetb group is optionally substituted by one or more r4d substituents.. . ... Heptares Therapeutics Limited

4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 modulators

The disclosures herein relate to novel compounds of formula wherein r1, r2, r3 and r4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychiatric disorders associated with modulating mglu5 receptor function.. . ... Heptares Therapeutics Limited

Bicyclic aza compounds as muscarinic m1 receptor antagonists

This invention relates to compounds (formula (1)) that are agonists of the muscarinic m1 receptor and which are useful in the treatment of muscarinic m1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. ... Heptares Therapeutics Limited

Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists

. . This invention relates to compounds that are agonists of the muscarinic m1 receptor and/or m4 receptor and which are useful in the treatment of muscarinic m1/m4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. ... Heptares Therapeutics Limited

Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists

The present invention provides muscarinic m4 receptor agonists of formula (i) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, r2 and r3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of diseases such as schizophrenia, alzheimer's disease and various cognitive disorders as well as in the treatment or alleviation of pain.. . ... Heptares Therapeutics Limited

Muscarinic m1 receptor agonists

This invention relates to compounds that are agonists of the muscarinic m1 receptor and which are useful in the treatment of muscarinic m1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. ... Heptares Therapeutics Limited

Muscarinic receptor agonists

. . This invention relates to compounds that are agonists of the muscarinic m1 receptor and which are useful in the treatment of muscarinic m1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. ... Heptares Therapeutics Limited

Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists

. . This invention relates to compounds that are agonists of the muscarinic m1 receptor and/or m4 receptor and which are useful in the treatment of muscarinic m1/m4 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. ... Heptares Therapeutics Limited








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Heptares Therapeutics Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Heptares Therapeutics Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###